Cardinal Health announced it has entered into a binding Letter of Intent to extend its existing pharmaceutical distribution agreement with CVS Health through June 30, 2032, continuing the current scope of distribution services. "We value our long-standing partnership with CVS Health and look forward to continuing to bring our best-in-class capabilities together to serve their customers," said Cardinal Health CEO Jason Hollar. In connection with the renewal, Cardinal Health reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, along with its long-term non-GAAP EPS growth rate guidance of 12% to 14%. The company said further updates may be provided during its upcoming first quarter earnings call on November 5, 2026.
Cardinal Health IncCardinal Health signed a binding LOI to extend its CVS pharmaceutical distribution agreement through 2032, securing continued distribution volume.
CVS Health CorpCVS Health is the counterparty extending its distribution agreement with Cardinal Health, but the article gives no independent financial detail on CVS.
